Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: The Research on Adverse Drug
Events and Reports (RADAR) project described in the Special Communication
by Dr Bennett and colleagues1 shows how a focused
research team can aid postmarketing surveillance by actively investigating
potential adverse drug reactions (ADRs). Operating out of a National Cancer
Institute–designated comprehensive cancer center, the RADAR project
is well-configured to address cancer and hematopoietic-related ADRs, an important
category of adverse events often associated with drug exposures. Other organ-based
specialists, such as hepatologists involved with the Drug Induced Liver Injury
Network,2 similarly offer insights into drug-related
illnesses of patients in their care.
Trontell AE. The RADAR Project and the FDA. JAMA. 2005;294(10):1206-1207. doi:10.1001/jama.294.10.1206-a